Instructions for Authors 2016

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**Nomenclature and Abbreviations.** Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey’s Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (http://www.gene.ucl.ac.uk/). Approved mouse nomenclature may be obtained from http://www.informatics.jax.org/. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

**Ethical Policies and Standards.** ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html

In case a submission is incomplete, the corresponding Author will be notified accordingly.

Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online annual subscription to Anticancer Research for the current year. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

**Specific information and additional instructions for Authors**

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.

2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees. (For further information please click here)

3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

6. Authors should pay attention to the following points when writing an article for AR:
- The Instructions to Authors must be followed in every detail.
- The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
- The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
- Results given in figures should not be repeated in tables.
- Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
- Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
- Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
- Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
- Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
- The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
- By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

9. Articles submitted to AR may be rejected without review if:
- they do not fall within the journal's policy.
- they do not follow the instructions to authors.
- language is unclear.
- results are not sufficient to support a final conclusion.
- results are not objectively based on valid experiments.
- they repeat results already published by the same or other authors before the submission to AR.
- plagiarism is detected by plagiarism screening services.

(Rejection rate (2015): 64%).

10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org

12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.

(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright © 2016 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
General Policy

IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.

One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH. The IIAR is a member of UICC.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

Selection of Recent Articles


Effects of Targeted Proton Radiation on Spinal Cord in a Porcine Model: A Pilot Study. X.W. MAO, M.J. PECAUT, J.D. CAO, D.S. GRIDLEY (Loma Linda, CA, USA)


Radical-scaping and Anti-inflammatory Activity of Quercetin and Related Compounds and Their Combinations Against RAW264.7 Cells Stimulated with Porphyromonas gingivalis Fimbriae. Relationships between Anti-inflammatory Activity and Quantum Chemical Parameters. Y. MURAKAMI, A. KAWATA, S. ITO, T. KATAYAMA, S. FUJISAWA (Sakado, Saitama; Tokyo, Japan)


Management of Very Early-onset Fetal Growth Restriction: Results from 92 Consecutive Cases. F. HOELLEN, A. BECKMANN, C. BANZ-JANSEN, J. WEICHERT, A. RODY, M.K. BOHLMANN (Liebeck; Mannheim, Germany)


The Prolonged QT Interval: Role of Pro-inflammatory Cytokines, Reactive Oxygen Species and the Ceramide and Sphingosine-1 Phosphate Pathways. P.P. SORDILLO, D.C. SORDILLO, L. HELSON (Quakertown, PA, USA)

Specific Antibodies to Staphylococcus aureus Biofilm Are Present in Serum from Pigs with Osteomyelitis. L.K. JENSEN, H.E. JENSEN, J. KOCH, T. BJARNSHOLT, S. EICKHARDT, M. SHIRTLIFF (Copenhagen, Denmark; Baltimore, MD, USA)
General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal’s scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the International Institute of Anticancer Research (IIAR) and is available online with Stanford University HighWire Press. The IIAR is a member of UICC. For more information please visit our website www.cgp.iiarjournals.org.

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 5339.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

A Selection of Recent Articles

Identification of Novel Biomarker and Therapeutic Target Candidates for Diagnosis and Treatment of Follicular Adenoma. X. LAI, S. CHEN (Indianapolis, IN, USA)

A Low-density Antigen Array for Detection of Disease-associated Autoantibodies in Human Plasma. R.I. SOMIARI, R. SUTPHEN, K. RENGANATHAN, S. RUSSELL, E. PASTWA, S.A. SOMIARI (Johnstown; Windber, PA; Tampa, FL, USA)

WNT/β-catenin Signaling Pathway and Downstream Modulators in Low- and High-grade Glioma. T. DENYSENKO, L. ANNO-VAZZI, P. CASSONI, A. MELCARNE, M. MELLAI, D. SCHIFFER (Vercelli; Turin, Italy)

Identification of Endogenous Controls for Use in miRNA Quantification in Human Cancer Cell Lines. M.K. DAS, R. ANDREASSEN, T.B. HAUGEN, K. FURU (Oslo, Norway)


Doxorubicin Affects Expression of Proteins of Neuronal Pathways in MCF-7 Breast Cancer Cells. M. PETROVIC, C. SIMILLION, P. KRUZLIAK, J. SABO, M. HELLER (Kosice, Slovak Republic; Bern, Switzerland; Brno, Czech Republic)

Molecular Mechanisms of Bone Metastasis. U.H. WEIDLE, F. BIRZELE, G. KOLLMORGGEN, R. RUGER (Penzberg, Germany)

Identification of Prognostically Relevant Chromosomal Abnormalities in Routine Diagnostics of Multiple Myeloma Using Genomic Profiling. E. KJELDSENE (Aarhus, Denmark)

MTA1 Is Up-regulated in Colorectal Cancer and Is Inversely Correlated with Lymphatic Metastasis. J. LI, L. YE, P.-H. SUN, L. SATHERLEY, R. HARGEST, Z. ZHANG, W.G. JIANG (Cardiff, UK; Beijing, PR China)


Significant Association of Caveolin-1 and Caveolin-2 with Prostate Cancer Progression. S. SUGIE, S. MUKAI, K. YAMASAKI, T. KAMIBEPPU, H. TSUKINO, T. KAMOTO (Miyazaki, Japan)

Delayed 5-Fluorouracil Toxicity with Uridine Triacetate in Patients with Dihydropyrimidine Dehydrogenase Deficiency. M.W. SAIF, R.B. DIASIO (Boston, MA; Rochester, MN, USA)
Subscription Order Form 2016

☐ Please enter a Subscription to ANTICANCER RESEARCH Volume 36 (2016).
Annual subscription rates (2016): Institutional, US$1898.00 online, US$2277.00 online & print; Personal, US$897.00 online; US$1277.00 online & print; Prices include rapid delivery and insurance.
☐ Please send me the following previous volumes (1-35) at 50% discount on the above rates.
☐ Please invoice.
☐ Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address: .............................................................................................................. ..................................................
..................................................................................................................................................................................................
Tel: .......................................................................................................................... ..............................................................
Fax: ....................................................................................................................... e-mail: ..............................................
Signature:............................................................................................................... Date:..................................................

Please send this order to ANTICANCER RESEARCH, Subscription Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: subscriptions@iiar-anticancer.org

Special 2016 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2016 on a basis of priority and availability. Effective from January to December 2016).

• Included in Pubmed, Current Contents and all abstracting and indexing services
• Online with Stanford University HighWire Press
• Open access articles

Please complete and send this order form to:
ANTICANCER RESEARCH, International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. e-mail: subscriptions@iiar-anticancer.org

Special Subscription Order Form 2016

☐ I am one of the authors of the article published in Anticancer Research Vol.………, pp. ………, year ……….
☐ Please enter my personal subscription to Anticancer Research 2016 (Volume 36) at the special Author’s rate of US$465.00 (print or online).
☐ Please send me previous Volume No(s) ……….. at US$224.00 (print) per volume.
☐ Please enter my personal combined 2016 subscription to Anticancer Research (Volume 36) and IN VIVO (Volume 30) at US$644.00 (print or online).
☐ Please send me an invoice.
Prices include rapid delivery and insurance.

Name and address: .............................................................................................................. ..................................................
..................................................................................................................................................................................................
Tel-Fax: ....................................................................................................................... ....................................................................................
e-mail: ..............................................................................................................................................................................................................
Date and signature: ..............................................................................................................

Lymphoma of the Cervix: Case Report and Review of the Literature. Z. Hilal, F. Hartmann, A. Dogan, C. Cetin, H. Krentel, S. Schiermeier, B. Schultheis, C.B. Tempfer (Bochum; Herne; Witten, Germany) .................................................................................................................. 4931

Outcomes After Whole-brain Radiotherapy for Brain Metastases with 5×4 Gy: Importance of Overall Treatment Time. D. Rades, T. Veninga, S. Janssen, S.E. Schild (Lubeck, Germany; Tilburg, the Netherlands; Scottsdale, AZ, USA) ........................................................................................................................ 4941

Bevacizumab for Ovarian Cancer at High Risk of Progression: Reproducibility of Trial Results in ‘Real-world’ Patients. G. Bertelli, F. Drews, K. Lutchman-Singh (Swansea, UK) .................................................. 4947


Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients. I. Kiss, J. Mlcochova, Z. Bortlicek, A. Poprach, J. Drabek, P. Vychytilova-Faltejskova, M. SVOBODA, T. Buchler, S. Batko, A. Ryska, M. Hajduch, O. Slaby (Brno; Olomouc; Prague; Hradec Kralove, Czech Republic) .............. 4955


Prevention and Treatment of Cancer: Hypes and Hopes 6th International Translational Cancer Research Conference. P. Patel, H. Vora, B.B. Aggarwal, V. Gandhi, K. Mehta, S. Pathak (Ahmedabad, India; Houston, TX, USA) ........................................ 4971

Errata ........................................................................................................................................................................ 4977

Book Reviews .......................................................................................................................................................... 4979

Forthcoming Papers .................................................................................................................................................. 4981


Sentinel Lymph Node Detection by Blue Dye Versus Indocyanine Green Fluorescence Imaging in Colon Cancer. G. LIBERALE, S. VANKERCKHOVE, M.G. GALDON, D. LARLIMONT, B. AHMED, F. BOUAZZA, M. MOREAU, I. EL NAKADI, V. DONCKIER, P. BOURGEOIS (Brussels, Belgium) .............. 4853


Impact of Neoadjuvant Chemotherapy on the Rate of Bowel Resection in Advanced Epithelial Ovarian Cancer. C.-A. PHILIP, A. PELLISSIER, C. BONNEAU, D. HEQUET, R. ROUZIER, N. POUGET (Saint Cloud; Villerbanne; St-Quentin-en-Yvelines, France) ............................................................................................................................. 4865


Survival Trends in Elderly Patients with Glioblastoma in the United States: a Population-based Study. B.K. SHAH, A. BISTA, S. SHARMA (Sedro-Woolley, WA; Sayre, PA, USA)......................................................................................................................... 4883


Prophylactic Robotic-assisted Laparoscopic Radical Prostatectomy for Preoperative Suspicion of Prostate Cancer: Experience with 55 Cases. Y.-C. OU, W.-C. WENG, K.-S. CHANG, C.-E. MEI, C.K. YANG, S.-W. HUNG, J. WANG, M.-C. TUNG (Taichung; Taipei, Taiwan, ROC) ................................................................................................................. 4895

Feasibility and Safety of Laparoscopic Total Mesometrial Resection in Early-stage Cervical Cancer. S. NASSER, J. ALMUHEIMID, H. PLETT, J. SEHOULI, M.Z. MUALLEM (Berlin, Germany) ................................................................. 4903


Insurance Status and Other Non-biological Factors Predict Outcomes in Acute Myelogenous Leukemia: Analysis of Data from the National Cancer Database. S. MASTER, R. MUNKER, Z. SHI, G. MILLS, R. SHI (Shreveport, LA; New York, NY, USA)................................................................................................................... 4915

Contents continued on the preceding page

Laparoscopy-assisted Proximal Gastrectomy with Double Tract Anastomosis Is Beneficial for Vitamin B12 and Iron Absorption. D.J. KIM, W. KIM (Seoul, Republic of Korea) ........................................................................... 4753


Assocation of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer – The SUCCESS Trial. P. HEPP, U. ANDERGASSEN, B. JÄGER, E. TRAPP, M. ALUNNI-FABBRO, T.W.P. FRIEDL, N. HECKER, R. LORENZ, P. FASCHING, A. SCHNEEWEISS, T. FEHM, W. JANNI, B. RACK (Wuppertal; Munich; Düsseldorf; Ulm; Braunschweig; Erlangen; Heidelberg, Germany) ............................................................................................................................................. 4771

Local Therapies Can Improve Intracerebral Control in Patients with Cerebral Metastasis from Gynecological Cancers. L. DZIGGEL, S. JANSSSEN, A. BAJROVIC, T. VENINGA, N.T. TRANG, M.T. KHOA, S.E. SCHILD, D. RADES (Lübeck; Hannover; Hamburg, Germany; Tilburg, the Netherlands; Hanoi, Vietnam; Scottsdale, AZ, USA) .............................................................................................................................................. 4777

Tumour Budding Correlates with Aggressiveness of Cutaneous Squamous-cell Carcinoma. G. KARAYANNOPOLLOU, S. EUVRARD, J. KANITAKIS (Thessaloniki, Greece; Lyon, France) .............................................................. 4781

Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer. V. KULDA, O. TOPOLCAN, R. KUCERA, M. KRIPTEROVA, K. SRBECKA, M. HORA, O. HES, J. KLECKA, V. BABUSKA, M. ROUSAROVA, V. BENSON, M. PESTA (Pilsen; Prague, Czech Republic) ............................................................................................................................................. 4787

A Case of Vanishing Brain Metastasis in a Melanoma Patient on Nivolumab. A. BASNET, N. SAAD, S. BENJAMIN (Syracuse, NY, USA) ......................................................................................................................................................................................... 4795

Prediction of KRAS Mutation in Rectal Cancer Using MRI. Y.R. SHIN, K.A. KIM, S. IM, S.S. HWANG, K. KIM (Seoul; Suwon, Republic of Korea) ......................................................................................................................................................................................... 4799

Prognostic Role of BRAF Mutations in Colorectal Cancer Liver Metastases. E. PIKOULIS, G.A. MARGONIS, N. ANDREATOS, K. SASAKI, A. ANGELOU, G. POLYCHRONIDIS, A. PIKOULI, E. RIZA, T.M. PAWLIK, E. ANTONIOU (Athens, Greece; Baltimore, MD, USA; Heidelberg, Germany) ............................................................... 4805


Overall Survival After Whole-Brain Radiation Therapy for Intracerebral Metastases from Testicular Cancer. D. RADES, L. DZIGGEL, T. VENINGA, A. BAJROVIC, S.E. SCHILD (Lübeck; Hamburg, Germany; Tilburg, the Netherlands; Scottsdale, AZ, USA) ................................................................................................. 4817

Synchronous Type 1 Papillary Renal Cell Carcinoma in a Patient with Rectal Adenocarcinoma. J. PIAO, P. FRIEDMAN, S. SIDDIQUI, J. VEERAPONG, J.-P. LAI (Saint Louis, MO, USA) ......................................................................................................................................................... 4821

Contents continued on the preceding page
Inhibition of Fatty Acid Synthesis Induces Apoptosis of Human Pancreatic Cancer Cells. K. NISHI, K. SUZUKI, J. SAWAMOTO, Y. TOKIZAWA, Y. IWASE, N. YUMITA, T. IKEDA (Yokohama, Japan) .......... 4655

Clinical Studies

Tissue Microarray Is a Reliable Tool for the Evaluation of HER2 Amplification in Breast Cancer. D. FURRER, S. JACOB, C. CARON, F. SANSCHAGRIN, L. PROVENCHER, C. DIORIO (Quebec City, QC, Canada) ............... 4661


Feasibility of Concomitant Chemoradiotherapy in Daily Practice for Patients with NSCLC Stage III. F.S. VAN DER MEER, F.M.N.H. SCHRAMEL, M. VAN VULPEN, S.Y. EL SHAROUNI (Nieuwegein; Utrecht, the Netherlands) ...................................................................................................................................................... 4673

Strong KDM4B and KDM4D Expression Associates with Radioresistance and Aggressive Phenotype in Classical Hodgkin Lymphoma. H. BUR, K.-M. HAAPASAARI, T. TURPEENIHEJUHANEN, O. KUITTINEN, P. AUVINEN, K. MARIN, Y. SOINI, P. KARIHTALA (Oulu; Kuopio, Finland) .................... 4677

Comparison Between a Combined Transrectal and Transperineal Approach and a Transrectal Approach for Prostate Rebiopsy. Y. SHIDA, T. HAKARIYA, K. TAKEHARA, T. ONITA, Y. MIYATA, H. SAKAI (Nagasaki, Japan) ................................................. 4685

Prognostic Significance of Pre-treatment Serum C-Reactive Protein Level in Patients with Adenocarcinoma of the Uterine Cervix. B. BODNER-ADLER, O. KIMBERGER, C. SCHNEIDINGER, H. KÖBL, K. BODNER (Vienna, Austria) ................................................................................................................................. 4691

Prognostic Factors for Survival in Patients Treated with Multimodal Therapy for Anaplastic Thyroid Cancer. L. KÄSMANN, L. BOLM, S. JANSSSEN, D. RADES (Lübeck; Hannover, Germany) ..................................................... 4697


Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients. V. RACHAR, M. CZEJK, M. KITZMUELLER, P. BUCHNER, M. LICHTNECKERT, R. GREIL, H. GEILER, C. DITTRICH (Vienna; Salzburg, Austria) .......................................................... 4715

Hepatic Resection After Prehepatectomy Chemotherapy for Metastatic Colorectal Cancer: A Propensity-Matched Analysis. D. KAWAGUCHI, Y. HIROSHIMA, K. MATSUO, I. ENDO, K. KODA, K. TANAKA (Chiba; Yokohama, Japan) .................................................. 4725

Parenchymal Congestion Is Important for Rapid Regeneration of the Future Liver Remnant Following the ALPPS Procedure. D. KAWAGUCHI, Y. HIROSHIMA, K. MATSUO, I. ENDO, K. KODA, K. TANAKA (Chiba; Yokohama, Japan) .................................................. 4731

BILLCD8 – A Multivariable Survival Model as a Simple and Clinically Useful Prognostic Tool to Identify High-risk Cutaneous Melanoma Patients. P. DONIZY, P. BIECEK, A. HALON, R. MATKOWSKI (Wroclaw; Warsaw, Poland) ................................................................................................. 4739

Contents continued on the preceding page
MEK Inhibitor Suppresses Expression of the miR-17-92 Cluster with G1-Phase Arrest in HT-29 Human Colon Cancer Cells and MIA PaCa-2 Pancreatic Cancer Cells. R. TANAKA, M. TOMOSUGI, T. SAKAI, Y. SOWA (Kyoto, Japan) .................................................................................................................................................. 4537

Altered Expression of PRKX, WNT3 and WNT16 in Human Nodular Basal Cell Carcinoma. N.G. DO CARMO, L.H.T. SAKAMOTO, R. POGUE, C.D. COUTO MASCARENHAS, S.K. PASSOS, M.S. SOARES FELIPE, R.V. DE ANDRADE (Brasília, DF; Campinas, SP, Brazil) .................................................................................................................. 4545

Significance of Expression of Complement C4d in Esophageal Squamous Cell Carcinoma. M. KIKUCHI, M. NAKAJIMA, H. MUROI, M. TAKAHASHI, J. ITOH, S. YAMAGUCHI, K. SASAKI, H. KATO (Mibu, Japan) ........................................................................................................................................................................... 4553

Extracellular Matrix-dependent Pathways in Colorectal Cancer Cells Reveal Potential Targets for Anticancer Therapies. V. STANKEVIČIUS, G. VASAUSKAS, R. NOREIKIENE, K. KUODYTE, M. VALIUS, K. SUZIEDELIS (Vilnius, Lithuania) .............................................................................................................. 4559

Photodynamic Diagnosis of Hepatocellular Carcinoma Using 5-Aminolevulinic Acid. M. NISHIMURA, Y. MURAYAMA, K. HARADA, Y. KAMADA, R. MORIMURA, H. IKOMA, D. ICHIKAWA, H. FUJWARA, K. OKAMOTO, E. OTSUJI (Kyoto, Japan) ............................................................................................................................................ 4569


AXIN1 Expression and Localization in Meningiomas and Association to Changes of APC and E-cadherin. N. PEČINA-ŠLAUS, A. KAFKA, T. VLADUŠIĆ, H.I. PEČINA, R. HRAŠČAN (Zagreb, Croatia) .............. 4583

Evaluating the Effect of Micropump© Position, Internal Pressure and Doxorubicin Dosage on Efficacy of Pressurized Intra-peritoneal Aerosol Chemotherapy (PIPAC) in an Ex Vivo Model. V. KHOSRAWIPOUR, T. KHOSRAWIPOUR, T.A. FALKENSTEIN, D. DIAZ-CARBALLO, E. FÖRSTER, A. OSMA, I.A. ADAMIETZ, J. ZIEREN, K. FAKHRIAN (Herne, Germany) ............................................................................ 4595

Electroinduced Delivery of Hydrogel Nanoparticles in Colon 26 Cells, Visualized by Confocal Fluorescence System. S. ATANASOVA, B. NIKOLOVA, S. MURAYAMA, E. STOYANOVA, I. TSONEVA, Z. ZHELEV, I. AOKI, R. BAKALOVA (Sofia; Stara Zagora, Bulgaria; Chiba, Japan) ........................................................................................................................................... 4601

Mutation Screening of Her-2, N-ras and Nf1 Genes in Brain Tumor Biopsies. C. YAPIJAKIS, M. ADAMOPOULOU, K. TASIOUKA, C. VOUMVOURAKIS, G. STRANJALIS (Athens, Greece) .................................................................................................................................................. 4607

Generation of Human Antibodies Against a Specific Peptide: a Novel Strategy Based on Human Cells. M. TOLOUDI, M. PAPADIMITRIOU, K. PANTOPIKOU, I. PAPASOTIRIOU (Florina, Greece) .................................................................................................................................................. 4613

GADD34 Promotes Tumor Growth by Inducing Myeloid-derived Suppressor Cells. L. LIU, S. ITO, N. NISHIO, Y. SUN, Y. TANAKA, K.-I. ISOBE (Nagoya, Japan) ........................................................................................................................................... 4623


Correlation Between Poor Prognosis and Lower TPPP Gene Expression in Hepatocellular Carcinoma. Y. INOKAWA, F. SONOHARA, M. KANDA, M. HAYASHI, Y. NISHIKAWA, H. SUGIMOTO, Y. KODERA, S. NOMOTO (Nagoya, Japan) .................................................................................................................................................. 4639

Pivotal Roles of Ginsenoside Rg3 in Tumor Apoptosis Through Regulation of Reactive Oxygen Species. H.Y. SUN, J.H. LEE, Y.-S. HAN, Y.M. YOON, C.W. YUN, J.H. KIM, Y.S. SONG, S.H. LEE (Seoul; Cheonan, Republic of Korea; Baltimore, MD, USA) .................................................................................................................................................. 4647
Color-coded Imaging Enables Fluorescence-guided Surgery to Resect the Tumor Along with the Tumor Microenvironment in a Syngeneic Mouse Model of EL-4 Lymphoma. K. HASEGAWA, A. SUETSUGU, M. NAKAMURA, T. MATSUMOTO, T. KUNISADA, M. SHIMIZU, S. SAJI, H. MORIWAKI, M. BOUVET, R.M. HOFFMAN (Gifu, Japan; San Diego, CA, USA) .......................................................... 4443

Silencing Prion Protein in HT29 Human Colorectal Cancer Cells Enhances Anticancer Response to Fucoidan. C.W. YUN, S. YUN, J.H. LEE, Y.-S. HAN, Y.M. YOON, D. AN, S.H. LEE (Seoul; Asa, Republic of Korea; Baltimore, MD, USA) .......................................................... 4449


CD40 Expression in Human Esophageal Squamous Cell Carcinoma Is Associated with Tumor Progression and Lymph Node Metastasis. Y. MATSUMURA, K. HIRAOKA, K. ISHIKAWA, YASUHITO SHOJI, T. NOJI, K. HONTANI, T. ITOH, T. NAKAMURA, T. TSUCHIKAWA, T. SHICHINOHE, S. HIRANO (Sapporo, Japan) .................................................................................................................................................... 4467

Non-toxic Efficacy of the Combination of Caffeine and Valproic Acid on Human Osteosarcoma Cells In Vitro and in Orthotopic Nude-mouse Models. K. IGARASHI, N. YAMAMOTO, K. HAYASHI, A. TAKEUCHI, H. KIMURA, S. MIWA, R.M. HOFFMAN, H. TSUCHIYA (San Diego, CA, USA; Kanazawa, Japan) ........ 4477

A Mouse Model of Fluorescent Protein-expressing Disseminated Peritoneal Lymphoma for Fluorescence-guided Surgery. T. MATSUMOTO, A. SUETSUGU, K. HASEGAWA, M. NAKAMURA, Y. SHIBATA, H. AOKI, T. KUNISADA, H. TSURUMI, M. SHIMIZU, M. BOUVET, R.M. HOFFMAN (Gifu, Japan; San Diego, CA, USA) .................................................................................................................................................... 4483

The Utility of Serum CA9 for Prognostication in Prostate Cancer. A.D. SMITH, M. TRUONG, R. BRISTOW, P. YIP, M.F. MILOSEVIC, A.M. JOSHUA (Toronto, ON, Canada) .................................................................................................................. 4489

Photodynamic Therapy Using Novel Glucose-conjugated Chlorin Increases Apoptosis of Cholangiocellular Carcinoma in Comparison with Talaporfin Sodium. G. MURAKAMI, A. NANASHIMA, T. NONAKA, T. TOMINAGA, K. WAKATA, Y. SUMIDA, H. AKASHI, S. OKAZAKI, H. KATAOKA, T. NAGAYASU (Nagasaki; Miyazaki; Okayama; Shizuoka; Nagoya, Japan) .................................................................................................................................................... 4493


Assessment of Promoter Methylation Identifies PTCH as a Putative Tumor-suppressor Gene in Human CLL. I.G.H. SCHMIDT-WOLF, C. PLASS, J.C. BYRD, K. FREVEL, T. PIETSCH, A. WAHA (Bonn, Germany; Columbus, OH, USA) .................................................................................................................................................... 4515


Th2 Dominance Might Induce Carcinogenesis in Patients with HCV-related Liver Cirrhosis. M. KOGAME, H. NAGAI, M. SHINOHARA, Y. IGARASHI, Y. SUMINO, K. ISHII (Tokyo, Japan) .................................................................................................................................................... 4529

Contents continued on the preceding page